Subscribe To
HUGE / FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder
HUGE News
By Accesswire
August 15, 2023
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HU more_horizontal
By Proactive Investors
January 30, 2023
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic p more_horizontal
By Proactive Investors
January 17, 2023
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS more_horizontal
By Proactive Investors
January 13, 2023
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up more_horizontal
By Proactive Investors
January 9, 2023
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. more_horizontal
By Proactive Investors
November 29, 2022
FSD Pharma announces changes to its board of directors
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L. more_horizontal
By Proactive Investors
September 6, 2022
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application fr more_horizontal
By Proactive Investors
May 31, 2022
FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration more_horizontal